The global Small Scale Bioreactors Market is estimated to be valued at US$ 1508.86 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Small scale bioreactors are employed for research, development and manufacturing of cell-based therapeutics and large-scale vaccines. They offer advantages such as lower construction costs, higher yields and ability to perform experiments in lesser volume of culture media.
Market key trends:
One of the key trends in the small scale bioreactors market is the growing demand for bioprocessing applications. Nowadays, bioprocessing is used for manufacturing of many pharmaceuticals such as vaccines, monoclonal antibodies, antibiotics etc. Small scale bioreactors play an important role in development and optimization of bioprocesses as they allow testing and validation of protocols in smaller volumes. They help understand the metabolic behavior of different cell lines and culture conditions before large scale production.
Strength: Small scale bioreactors offer flexibility and scalability for cell culture processes. Their compact size requires less space and investments.
Weakness: Small scale bioreactors have limited production capacities compared to large scale bioreactors. Process development and validation takes longer time and higher costs for commercial production.
Opportunity: Growing demand for biologics and cell-based therapies is driving the need for small scale bioreactors in research and development. Emerging markets in Asia Pacific offer growth opportunities.
Threats: Intense competition among existing players may lead to pricing pressures. Stringent regulatory approval process and quality standards poses challenges.
The global Small Scale Bioreactors Market Growth is expected to witness high growth, exhibiting a CAGR of 10% over the forecast period, due to increasing R&D investments in pharmaceutical and biotechnology industries.
Regional analysis: North America dominated the market in 2020 owing to presence of leading biopharma companies and availability of funding for R&D. Asia Pacific is expected to grow at fastest pace during the forecast period with increase in biosimilar manufacturing in China, India and Japan.
Key players operating in the small scale bioreactors market are Merck KGaA ,Danaher Corporation, Getinge AB, Sartorius AG ,Thermo Fisher Scientific Inc. , Lonza Group , Eppendorf AG , Miltenyi Biotec ,Solaris Biotechnology Srl, Infors AG, Biosan, MicroDigital Co. Ltd., 2mag AG, MDX Biotechnik International GmbH, Esco Lifesciences Group, HiTec Zang GmbH, Hanil Scientific Inc., Adolf KÃ1⁄4hner AG, Ori Biotech , Aglaris and AdvaBio.